Apyx Medical 配当と自社株買い
配当金 基準チェック /06
Apyx Medical配当金を支払った記録がありません。
主要情報
n/a
配当利回り
-5.5%
バイバック利回り
| 総株主利回り | -5.5% |
| 将来の配当利回り | n/a |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
更新なし
Recent updates
ナラティブの更新 • Jun 27
APYX: Expanded Body Contouring Clearances And Studies Will Support Bullish Repricing
Analysts have raised their price target for Apyx Medical to $6.00 from $5.00, citing updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E as key drivers of the change. What’s in the News for Apyx Medical Apyx Medical received expanded 510(k) clearance from the U.S. Food and Drug Administration for the AYON Body Contouring System to include power liposuction, enabling multiple body contouring modalities within one platform.
ナラティブの更新 • Jun 13
APYX: Expanded Body Contouring Platform Will Drive Future Upside Potential
Analysts have adjusted their price target on Apyx Medical to $6.50 from $6.50, reflecting updated assumptions around the discount rate, profit margin and future P/E, while keeping fair value and revenue growth expectations unchanged. What's in the News Apyx Medical received expanded 510(k) clearance from the U.S. Food and Drug Administration for the AYON Body Contouring System to include power liposuction, allowing multiple body contouring modalities within one platform.ナラティブの更新 • May 30
APYX: GLP 1 Skin Tightening Demand Will Drive Future Upside
Apyx Medical's analyst price target has shifted to $6.50 from $6.40, as analysts point to a higher Street target around $6; recent research highlighting stronger guidance into 2026; potential upside from liposuction handpiece approval; and growing international and GLP-1 related demand, alongside updated assumptions for slightly faster revenue growth, a lower discount rate, modestly lower profit margins, and a reduced future P/E multiple. Analyst Commentary Recent Street research highlights a mix of optimism and caution around Apyx Medical, with attention on execution against 2026 guidance, new products, and international expansion.分析記事 • May 11
Earnings Update: Here's Why Analysts Just Lifted Their Apyx Medical Corporation (NASDAQ:APYX) Price Target To US$6.50
Apyx Medical Corporation ( NASDAQ:APYX ) investors will be delighted, with the company turning in some strong numbers...ナラティブの更新 • May 05
APYX: GLP 1 Skin Tightening And New Tools Will Drive Upside
Analysts have raised their Apyx Medical price target to $6 from $5, citing a stronger recent quarter, higher 2026 guidance and added potential from new product approvals, geographic expansion and growing demand linked to GLP-1 usage. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent quarter, where sales were in line and earnings were ahead of expectations, as support for a higher valuation framework.ナラティブの更新 • Apr 21
APYX: GLP-1 Skin Tightening Demand Will Support Future Upside
Analysts have lifted their price targets on Apyx Medical to $6, up from $5, citing a strong quarter; 2026 guidance above prior Street expectations; early traction from the Ayon launch; and potential upside from new product approvals, GLP-1 related skin tightening demand, and international expansion. Analyst Commentary Bullish Takeaways Bullish analysts see the new $6 price target as reflecting stronger confidence in execution after a quarter where sales were in line and earnings were ahead of prior expectations, which they view as supportive for valuation.ナラティブの更新 • Apr 05
APYX: GLP-1 Skin Tightening Trend Will Drive Future Upside
Narrative Update on Apyx Medical The updated analyst price target for Apyx Medical moves to $6, with analysts pointing to a strong quarter, 2026 guidance that is ahead of Street expectations, early traction from the Ayon launch, growing skin tightening demand linked to GLP-1 usage, and expansion opportunities outside the U.S. as key supports for the change. Analyst Commentary Recent Street research on Apyx Medical centers on a higher $6 price target and an upgrade to a more constructive stance, driven by operational updates, new product traction, and exposure to GLP-1 related demand trends.ナラティブの更新 • Mar 22
APYX: GLP-1 Procedure Demand And International Expansion Will Drive Future Upside
Narrative Update: Apyx Medical Apyx Medical's updated fair value estimate edges up from $6.00 to $6.40 as analysts point to a higher Street price target of $6.00, recent earnings outperformance, 2026 guidance that sits above prior expectations, and additional growth opportunities tied to new product approvals, GLP-1 related demand, and international expansion. Analyst Commentary Recent Street commentary on Apyx Medical is broadly constructive, with analysts pointing to a combination of product momentum, new procedure use cases, and international expansion as key inputs to their updated valuation work.ナラティブの更新 • Mar 06
APYX: Strong Revenue Outlook Will Support Future Single Platform Adoption
Analysts have raised their Apyx Medical price target to $6.00, up from $6.00, citing updated assumptions around revenue growth, profit margins, the discount rate and future P/E that together refine their view of the stock's risk and earnings potential. What's in the News Apyx Medical issued preliminary revenue guidance for fourth quarter 2025, with management expecting revenue between $19.0 million and $19.2 million, which the company states represents a 34% year over year increase (Key Developments).ナラティブの更新 • Feb 19
APYX: Single Console Platform Will Drive Future Adoption And Margin Expansion
Analysts have modestly adjusted their price target framework for Apyx Medical, reflecting updated assumptions around profit margin and future P/E that contribute to a refined view of fair value at $6.00 per share. What's in the News Apyx Medical issued preliminary revenue guidance for the fourth quarter of 2025, with expected revenue between $19.0m and $19.2m, described by the company as approximately 34% year over year growth (company guidance).ナラティブの更新 • Feb 03
APYX: Single Console Platform Will Drive Wider Adoption And Margin Expansion
Narrative Update on Apyx Medical Analysts have raised their price target on Apyx Medical to US$8, reflecting increased confidence that the AYON all in one console, which integrates Renuvion with additional surgical offerings, can attract physicians through its differentiated technology, workflow benefits, and broad patient appeal. Analyst Commentary Recent research updates are framing Apyx Medical as a company where expectations are increasingly tied to execution on the AYON platform and its potential impact on growth, margins, and valuation.分析記事 • Feb 03
Subdued Growth No Barrier To Apyx Medical Corporation (NASDAQ:APYX) With Shares Advancing 26%
Despite an already strong run, Apyx Medical Corporation ( NASDAQ:APYX ) shares have been powering on, with a gain of...ナラティブの更新 • Jan 20
APYX: Single Console Platform Will Support Future Procedure And Workflow Adoption
Analysts have raised their price target on Apyx Medical to $8, pointing to the AYON system's integrated console design, use of the legacy Renuvion technology, and its appeal to physicians as key supports for the updated view. Analyst Commentary Recent analyst commentary around Apyx Medical has focused on how the AYON system could influence the company’s growth path, execution risks, and valuation framework.分析記事 • Jan 13
Is Apyx Medical Corporation (NASDAQ:APYX) Trading At A 45% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Apyx Medical fair value estimate is US$7.24 Apyx Medical is...ナラティブの更新 • Jan 06
APYX: Single Console Platform Will Drive Future Procedure Adoption Upswing
Analysts have nudged their fair value target for Apyx Medical to $6.00 per share, citing greater confidence in the AYON system's all in one console design and its potential appeal to physicians and a broadening patient base. Analyst Commentary Bullish Takeaways Bullish analysts point to the AYON system's all in one, single console design as a core driver for their higher fair value targets, arguing that a unified platform can support more efficient procedure volumes and revenue per installed unit over time.ナラティブの更新 • Dec 22
APYX: New Surgical Console Rollout Will Drive Stronger Demand Inflection
Analysts have modestly raised their price target on Apyx Medical to $8.00, citing increasing confidence that the AYON system can drive faster adoption and enhance the company’s long term growth and profitability profile. Analyst Commentary Analyst feedback on Apyx Medical has been largely constructive, with the AYON system viewed as a key catalyst for accelerating revenue growth and improving the company’s valuation profile.ナラティブの更新 • Dec 08
APYX: Workflow Console Rollout Will Drive Bullish Demand Inflection
Analysts have raised their price target on Apyx Medical to $8.00, citing increasing optimism that the AYON all in one console, which integrates the company's Renuvion technology with multiple surgical offerings, can drive an inflection in demand by streamlining workflows and addressing a large, growing patient base. Analyst Commentary Recent research notes highlight a shift in sentiment as bullish analysts point to AYON as a key driver of Apyx Medical's next phase of growth, underpinning the higher price target.ナラティブの更新 • Nov 24
APYX: Recent Product Launch and Equity Raise Will Drive Share Momentum
Analysts have raised their price target for Apyx Medical from $4.50 to $6.00 per share, citing increased growth prospects supported by the successful launch and strong physician appeal of the AYON system. Analyst Commentary Recent analyst feedback reflects a growing optimism around Apyx Medical's outlook, particularly in light of the momentum generated by the AYON system launch and its integration of legacy technology and new surgical offerings.分析記事 • Nov 18
Apyx Medical Corporation's (NASDAQ:APYX) Shares Leap 38% Yet They're Still Not Telling The Full Story
Despite an already strong run, Apyx Medical Corporation ( NASDAQ:APYX ) shares have been powering on, with a gain of...分析記事 • Nov 07
Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)?
Apyx Medical Corporation ( NASDAQ:APYX ), is not the largest company out there, but it received a lot of attention from...ナラティブの更新 • Nov 07
APYX: Earnings Guidance Increase Will Drive Market Expansion Opportunities
Narrative Update on Apyx Medical: Analyst Price Target Revision Analysts have raised their price target for Apyx Medical from $4.00 to $4.50 per share. This change is attributed to improved profitability and a lower discount rate, even though there is a reduction in projected revenue growth.分析記事 • Oct 04
Even With A 26% Surge, Cautious Investors Are Not Rewarding Apyx Medical Corporation's (NASDAQ:APYX) Performance Completely
Apyx Medical Corporation ( NASDAQ:APYX ) shareholders would be excited to see that the share price has had a great...分析記事 • Sep 19
Is Apyx Medical (NASDAQ:APYX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jul 26
A Piece Of The Puzzle Missing From Apyx Medical Corporation's (NASDAQ:APYX) 34% Share Price Climb
Despite an already strong run, Apyx Medical Corporation ( NASDAQ:APYX ) shares have been powering on, with a gain of...分析記事 • Apr 23
The Market Doesn't Like What It Sees From Apyx Medical Corporation's (NASDAQ:APYX) Revenues Yet As Shares Tumble 25%
To the annoyance of some shareholders, Apyx Medical Corporation ( NASDAQ:APYX ) shares are down a considerable 25% in...
新しいナラティブ • Apr 11
AYON Launch And Restructuring Will Create Lasting Opportunities
The launch of the AYON Body Contouring System may significantly drive revenue growth through market expansion and increased equipment sales.分析記事 • Mar 05
Apyx Medical Corporation's (NASDAQ:APYX) Shares Lagging The Industry But So Is The Business
With a price-to-sales (or "P/S") ratio of 0.9x Apyx Medical Corporation ( NASDAQ:APYX ) may be sending very bullish...分析記事 • Dec 19
Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)?
While Apyx Medical Corporation ( NASDAQ:APYX ) might not have the largest market cap around , it led the NASDAQGS...分析記事 • Nov 23
Apyx Medical Corporation (NASDAQ:APYX) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Apyx Medical Corporation ( NASDAQ:APYX ) shareholders would be excited to see that the share price has had a great...分析記事 • Sep 14
Is There An Opportunity With Apyx Medical Corporation's (NASDAQ:APYX) 41% Undervaluation?
Key Insights The projected fair value for Apyx Medical is US$1.98 based on 2 Stage Free Cash Flow to Equity Apyx...分析記事 • Aug 07
Apyx Medical Corporation (NASDAQ:APYX) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Apyx Medical Corporation ( NASDAQ:APYX ) shareholders that were waiting for something to happen have been dealt a blow...分析記事 • Aug 01
We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed
Key Insights Apyx Medical will host its Annual General Meeting on 8th of August Salary of US$482.5k is part of CEO...分析記事 • Jun 19
Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Apr 18
Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive
Unfortunately for some shareholders, the Apyx Medical Corporation ( NASDAQ:APYX ) share price has dived 25% in the last...決済の安定と成長
配当データの取得
安定した配当: APYXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: APYXの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| Apyx Medical 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (APYX) | n/a |
| 市場下位25% (US) | 1.3% |
| 市場トップ25% (US) | 4.1% |
| 業界平均 (Medical Equipment) | 2.0% |
| アナリスト予想 (APYX) (最長3年) | n/a |
注目すべき配当: APYXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: APYXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: APYXの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: APYXが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/04 06:08 |
| 終値 | 2026/07/02 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Apyx Medical Corporation 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Michael Gorman | BTIG |
| Sam Eiber | BTIG |
| David Turkaly | Citizens JMP Securities, LLC |